Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSA | P10619 | 15/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4341782 | 1.00 | CTSA (0.43) | CTSACYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4325425 | 0.94 | CTSA (0.45) | CTSACYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4325161 | 0.90 | SLC6A9 (0.48) | CTSACYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4325332 | 0.90 | SLC6A9 (0.48) | CTSACYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4333128 | 0.90 | CTSA (0.47) | CTSALMNA | |
| SCHEMBL4335210 | 0.90 | CTSA (0.47) | CTSALMNA | |
| SCHEMBL4326210 | 0.89 | CTSA (0.41) | CTSACYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4327564 | 0.89 | CTSA (0.43) | CTSACYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4343417 | 0.89 | CTSA (0.41) | CTSACYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4334693 | 0.89 | CTSA (0.43) | CTSACYP1A2CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7521563-B2 | Hydroxamic acid derivative and medicine containing the same as active ingredient | SHIZUOKA COFFEIN CO., LTD. (JP) | 2009-04-21 | — | — | US | disclosed |
| US-20070208065-A1 | Hydroxamic Acid Derivative and Medicine Containing the Same as Active Ingredient | SHIZUOKA COFFEIN CO., LTD. (JP) | 2007-09-06 | — | — | US | disclosed |
| EP-1787986-A1 | HYDROXAMIC ACID DERIVATIVE AND MEDICINE CONTAINING THE SAME AS ACTIVE INGREDIENT | SHIZUOKA COFFEIN CO., LTD. (JP) | 2007-05-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208065-A1 | Hydroxamic Acid Derivative and Medicine Containing the Same as Active Ingredient | IL6, IL1A, TNF | CTSA 1028/4885CYP1A2 1586/4885CYP3A4 2548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.